Comparative In Vitro Activities of Ciprofloxacin, Clinafloxacin, Gatifloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against Klebsiella pneumoniae , Klebsiella oxytoca , Enterobacter cloacae , and Enterobacter aerogenes Clinical Isolates with Alterations in GyrA and ParC Proteins-Reference-Cited by-同舟云学术

Comparative In Vitro Activities of Ciprofloxacin, Clinafloxacin, Gatifloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against Klebsiella pneumoniae , Klebsiella oxytoca , Enterobacter cloacae , and Enterobacter aerogenes Clinical Isolates with Alterations in GyrA and ParC Proteins

Published:1999-08 Issue:8 Volume:43 Page:2051-2055
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Brisse Sylvain¹,Milatovic Dana¹,Fluit Ad C.¹,Verhoef Jan¹,Martin Nele²,Scheuring Sybille²,Köhrer Karl²,Schmitz Franz-Josef¹²

Affiliation:

1. Eijkman-Winkler Institute, Utrecht University, 3584 CX, Utrecht, The Netherlands,1and

2. Institute for Medical Microbiology and Virology, University Hospital Düsseldorf, D-40225 Düsseldorf, Germany2

Abstract

ABSTRACT The in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin were tested against 72 ciprofloxacin-resistant and 28 ciprofloxacin-susceptible isolates of Klebsiella pneumoniae , Klebsiella oxytoca , Enterobacter cloacae , and Enterobacter aerogenes . Irrespective of the alterations in GyrA and ParC proteins, clinafloxacin exhibited greater activity than all other fluoroquinolones tested against K. pneumoniae and E. aerogenes .

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.43.8.2051

Reference21 articles.

1. High-level quinolone resistance amongst clinical isolates of Escherichia coli and Klebsiella pneumoniae from Spain.;Alarcon T.;J. Antimicrob. Chemother.,1993

2. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.;Bauernfeind A.;J. Antimicrob. Chemother.,1997

3. Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae.;Bauernfeind A.;J. Antimicrob. Chemother.,1994

4. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates.;Belland R. J.;Mol. Microbiol.,1994

5. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antimicrobial and Antiviral Materials a Review of Applications, and Mechanism of Action;2024

2. High antipersister activity of a promising new quinolone drug candidate in eradicating uropathogenic Escherichia coli persisters and persistent infection in mice;Journal of Applied Microbiology;2023-09

3. Carbapenem-Resistant and ESBL-Producing Enterobacterales Emerging in Central Texas;Infection and Drug Resistance;2023-03

4. A novel parC mutation potentiating fluoroquinolone resistance in Klebsiella pneumoniae and Escherichia coli clinical isolates;The Journal of Infection in Developing Countries;2022-02-28

5. Klebsiella oxytoca Complex: Update on Taxonomy, Antimicrobial Resistance, and Virulence;Clinical Microbiology Reviews;2022-01-19